OMER Stock: Omeros PT Set at $30.00 by HC Wainwright

0
288

Omeros (NASDAQ:OMER) has been given a $30.00 price target by investment analysts at HC Wainwright in a research note issued on Thursday, December 14th. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 49.18% from the stock’s previous close.

A number of other equities analysts have also weighed in on OMER. Maxim Group set a $24.00 price objective on Omeros and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Wedbush reaffirmed an “outperform” rating and issued a $47.00 price target on shares of Omeros in a research note on Friday, August 18th. Zacks Investment Research lowered Omeros from a “buy” rating to a “hold” rating in a research note on Wednesday, October 25th. Cantor Fitzgerald reissued a “hold” rating and set a $19.00 target price (up previously from $15.00) on shares of Omeros in a research note on Thursday, August 24th. Finally, Cowen lowered Omeros from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 2nd. Five research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Omeros presently has an average rating of “Buy” and an average price target of $34.14.

Shares of Omeros (NASDAQ:OMER) opened at $20.11 on Thursday. The company has a debt-to-equity ratio of 8.99, a quick ratio of 4.74 and a current ratio of 4.77. Omeros has a 12-month low of $8.71 and a 12-month high of $27.09. The company has a market capitalization of $965.36, a P/E ratio of -15.59 and a beta of 3.58.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.18. The firm had revenue of $21.66 million for the quarter, compared to analysts’ expectations of $17.82 million. The firm’s revenue for the quarter was up 91.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.34) earnings per share. analysts predict that Omeros will post -0.98 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in OMER. Teachers Advisors LLC increased its holdings in shares of Omeros by 7.8% in the 1st quarter. Teachers Advisors LLC now owns 68,285 shares of the biopharmaceutical company’s stock valued at $1,032,000 after acquiring an additional 4,951 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Omeros by 5.1% in the 1st quarter. Vanguard Group Inc. now owns 1,731,391 shares of the biopharmaceutical company’s stock valued at $26,179,000 after purchasing an additional 83,868 shares during the period. Morgan Stanley boosted its position in shares of Omeros by 20.1% in the 1st quarter. Morgan Stanley now owns 199,087 shares of the biopharmaceutical company’s stock valued at $3,010,000 after purchasing an additional 33,285 shares during the period. Schwab Charles Investment Management Inc. boosted its position in shares of Omeros by 5.5% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 195,117 shares of the biopharmaceutical company’s stock valued at $2,951,000 after purchasing an additional 10,194 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of Omeros by 7.8% in the 1st quarter. Bank of America Corp DE now owns 78,894 shares of the biopharmaceutical company’s stock valued at $1,193,000 after purchasing an additional 5,736 shares during the period. Institutional investors and hedge funds own 49.71% of the company’s stock.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros (NASDAQ:OMER)

LEAVE A REPLY

Please enter your comment!
Please enter your name here